Private company
2seventy bio, Inc.
American pharmaceutical preparations company based in Cambridge.
Last updated Oct 18, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
-304.9%Operating margin3
-151.2%Net margin3
-62.3%Revenue growth, 20243
-27.2%Return on equity3
-$85.7MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2024
- Research and development64¢$76.9M
- Selling, general and admin36¢$43.9M
Out of $37.9M in revenue.3 The company lost money this year.
Financial statements
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | $44.3M4 | $248.1M5 | $54.5M6 | $91.5M6 | $100.4M3 | $37.9M3 | |
| Cost of revenue | $3.0M4 | $5.4M5 | $2.5M6 | $1.7M6 | $2.1M3 | $03 | |
| Research and development | $297.6M4 | $296.5M5 | $252.6M6 | $248.7M6 | $230.8M3 | $76.9M3 | |
| Selling, general and admin | $81.6M4 | $90.9M5 | $93.5M6 | $79.5M6 | $69.4M3 | $43.9M3 | |
| Operating income | -$340.7M4 | -$138.2M5 | -$313.9M6 | -$263.1M6 | -$237.6M3 | -$115.4M3 | |
| Income tax | $04 | $05 | $06 | $06 | $03 | $03 | |
| Net income | -$320.6M4 | -$120.1M5 | -$292.2M6 | -$254.2M6 | -$217.6M3 | -$57.2M3 | |
| Earnings per share | -$13.724 | -$5.145 | -$12.446 | -$7.136 | -$4.423 | -$1.103 | |
| Earnings per share (diluted) | -$13.724 | -$5.145 | -$12.446 | -$7.136 | -$4.423 | -$1.103 |
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Cash | $04 | $04 | $05 | $130.4M6 | $71.0M6 | $75.0M3 | $71.2M3 |
| Current assets | $25.1M4 | $291.6M5 | $300.9M6 | $237.8M3 | $187.3M3 | ||
| Total assets | $312.6M4 | $759.7M5 | $656.7M6 | $565.4M3 | $479.5M3 | ||
| Current liabilities | $75.9M4 | $98.4M5 | $79.8M6 | $59.8M3 | $40.1M3 | ||
| Total liabilities | $238.0M4 | $399.9M5 | $346.2M6 | $310.1M3 | $268.7M3 | ||
| Shareholders’ equity | $28.0M4 | $43.7M5 | $74.6M6 | $359.8M6 | $310.5M3 | $255.3M3 | $210.8M3 |
| Shares outstanding | 0 shares4 | 23.6M shares5 | 37.9M shares6 | 50.6M shares3 | 51.6M shares3 |
Leadership
Who has led 2seventy bio, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerWilliam D. Baird Iii. Apr 3, 2024 to now10
- Chief executive officerNick Leschly Oct 18, 2021 to Apr 3, 202411
- PresidentWilliam D. Baird Iii. Apr 3, 2024 to now10
- PresidentNick Leschly Oct 18, 2021 to Apr 3, 202411
- Chief financial officerVictoria Eatwell Apr 3, 2024 to now12
- Chief financial officerWilliam D. Baird Iii. Oct 18, 2021 to Aug 24, 202313
- Chief operating officerJessica Snow Mar 19, 2025 to now14
- Chief operating officerWilliam D. Baird Iii. Jan 5, 2024 to Mar 19, 202515
- Chief operating officerNicola Heffron Nov 8, 2021 to Feb 9, 202316
Board members and other officers (12)
- OfficerJessica Snow Apr 3, 2024 to now17
- Chief Scientific OfficerPhilip D. Gregory Nov 8, 2021 to now18
- Board memberCharles W. Newton Mar 25, 2024 to now19
- Board memberEli Casdin Mar 25, 2024 to now20
- Board memberWilliam D. Baird Iii. Apr 3, 2024 to now10
- Board memberLin Wei Mar 9, 2023 to now21
- Board memberDenice Torres Oct 18, 2021 to now22
- Board memberMarcela Maus V. Oct 18, 2021 to now23
- Board memberNick Leschly Oct 18, 2021 to now11
- Board memberRamy Ibrahim Oct 18, 2021 to Jun 15, 202324
- Board memberSarah Js Glickman Oct 18, 2021 to now25
- Board memberWilliam R. Sellers Oct 18, 2021 to Nov 16, 202126
Timeline
Filings
325 filings to the SEC since October 2021: 6 annual reports, 14 quarterly reports, 76 major events, 135 insider forms, 30 large holders, 1 private raises, 63 other. The latest 20:
- Aug 14, 2025SCHEDULE 13G/A EDGAR
- Aug 14, 2025SCHEDULE 13G/A EDGAR
- Jun 6, 2025SCHEDULE 13G/A EDGAR
- May 23, 202515-12G EDGAR
- May 15, 20254 PRIMARY DOCUMENT EDGAR
- May 15, 20254 PRIMARY DOCUMENT EDGAR
- May 15, 20254 PRIMARY DOCUMENT EDGAR
- May 15, 20254 PRIMARY DOCUMENT EDGAR
- May 15, 20254 PRIMARY DOCUMENT EDGAR
- May 15, 20254 PRIMARY DOCUMENT EDGAR
- May 15, 20254 PRIMARY DOCUMENT EDGAR
- May 15, 20254 PRIMARY DOCUMENT EDGAR
- May 15, 20254 PRIMARY DOCUMENT EDGAR
- May 15, 20254 EDGAR
- May 13, 2025EFFECT EDGAR
- May 13, 2025POS AM EDGAR
- May 13, 2025S-8 POS EDGAR
- May 13, 2025S-8 POS EDGAR
- May 13, 2025S-8 POS EDGAR
- May 13, 2025S-8 POS EDGAR
The 325 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 30 such filings since October 2021, the latest 10:
- Aug 14, 2025SCHEDULE 13G/A
- Aug 14, 2025SCHEDULE 13G/A
- Jun 6, 2025SCHEDULE 13G/A
- Apr 30, 2025SCHEDULE 13G/A
- Apr 15, 2025SCHEDULE 13G
- Mar 18, 2025SCHEDULE 13G
- Mar 17, 2025SCHEDULE 13G/A
- Nov 6, 2024SC 13G/A
- Feb 14, 2024SC 13G/A
- Feb 14, 2024SC 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
- Mar 17, 2022Raised $170 million in a private offering of equity Form D: 22 investors so far Form D
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARJessica Snow, Officer
- 18
- 19SEC EDGARCharles W. Newton, Board member
- 20SEC EDGAREli Casdin, Board member
- 21SEC EDGARLin Wei, Board member
- 22SEC EDGARDenice Torres, Board member
- 23SEC EDGARMarcela Maus V., Board member
- 24SEC EDGARRamy Ibrahim, Board member
- 25SEC EDGARSarah Js Glickman, Board member
- 26SEC EDGARWilliam R. Sellers, Board member